Owlet Toekomstige groei
Future criteriumcontroles 1/6
De verwachting is dat Owlet de winst en omzet met respectievelijk 138.6% en 18% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 137.8% per jaar.
Belangrijke informatie
138.6%
Groei van de winst
137.79%
Groei van de winst per aandeel
| Medical Equipment winstgroei | 16.1% |
| Inkomstengroei | 18.0% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 19 May 2026 |
Recente toekomstige groei-updates
Recent updates
Seeking Alpha • May 18
Owlet: Telehealth And Subscriptions Could Drive The Next Leg Of Growth
Summary Owlet remains a buy despite mixed Q1 results and lowered revenue guidance, with the stock trading near post-selloff lows. Subscription growth, particularly Owlet 360, is driving higher gross margins, offsetting declining hardware sales and supporting the company’s transition to a pediatric health platform. Profitability guidance improved significantly, with adjusted EBITDA now expected at $7-$9 million, reflecting a sharper focus on profitable markets and cost control. Key risks include slowing hardware sales, elevated operating expenses, and recent CEO turnover, but OWLT’s low valuation and platform evolution offer attractive upside. Read the full article on Seeking Alpha
Narratiefupdate • May 11
OWLT: Softer Q1 Outlook Seen Setting Up Stronger 2026 Finish
Analysts have trimmed their price target on Owlet stock to $15 from $20, citing Q1 guidance that came in below expectations, while highlighting that 2026 guidance still lines up with prior views and points to a potentially stronger second half of that year. Analyst Commentary Bearish analysts are signaling a more cautious stance on Owlet after recent guidance, using the reduced price target as a way to reset expectations while still acknowledging longer term potential.Narratiefupdate • Apr 20
OWLT: Softer Q1 Outlook Expected To Set Up Stronger Second Half 2026
Analysts have lowered their price target on Owlet to $15 from $20, citing slightly softer Q1 guidance versus expectations. They also note that current management guidance indicates the second half of 2026 could be more robust.Narratiefupdate • Apr 05
OWLT: Guidance And Partnerships Are Expected To Support A Stronger Second Half 2026
Analysts have revised Owlet's price target to $15, down from $19, reflecting mixed near term guidance and updated models that still indicate the possibility of stronger performance in the longer term. Analyst Commentary Recent research updates on Owlet point to a more cautious tone, even as some longer term expectations remain in place.Narratiefupdate • Mar 22
OWLT: Updated Modeling And Healthcare Partnerships Will Support Stronger Second Half 2026
Analysts have updated their view on Owlet, trimming the consolidated price target to $15 as they factor in softer Q1 guidance, a higher assumed P/E multiple and lower projected revenue growth and profit margins, while still highlighting expectations for a stronger second half of 2026. Analyst Commentary Recent research highlights a more measured tone around Owlet, with some price targets recalibrated as analysts balance solid past execution with softer near term guidance and updated valuation assumptions.Narratiefupdate • Mar 08
OWLT: Updated Modeling And New Healthcare Partnerships Will Support Future Upside Potential
Analysts have adjusted their outlook on Owlet, trimming the price target from $14 to $13 as they factor in updated expectations for growth, profitability, and future P/E assumptions that are informed by recent research highlighting mixed near term guidance alongside longer term projections that are described as steady. Analyst Commentary Recent Street research reflects a mixed but increasingly cautious tone around Owlet, with some bearish analysts trimming price targets as they reassess growth visibility and execution risk against current valuation.Narratiefupdate • Feb 22
OWLT: Updated Modeling And FDA Pathways Will Support Future Upside Potential
Analysts have lifted their price target on Owlet to $19 from $15, citing updated modeling assumptions following a transfer of coverage. Analyst Commentary Recent research points to a reset in expectations around Owlet, with updated modeling used to support a US$19 price target.
Narratiefupdate • Feb 07
OWLT: Additional Liquidity And Partnerships Will Extend Funding Runway
Analysts have lifted their price target on Owlet to US$20 from US$15, citing updated models that factor in recent Street research highlighting a refreshed coverage framework and additional liquidity that supports the company’s plans. Analyst Commentary Bullish analysts are pointing to recent price target revisions as a sign of growing confidence in Owlet’s ability to execute on its plans, especially as fresh research coverage and additional liquidity are incorporated into updated models.Analyseartikel • Feb 05
Some Owlet, Inc. (NYSE:OWLT) Shareholders Look For Exit As Shares Take 31% Pounding
Owlet, Inc. ( NYSE:OWLT ) shares have retraced a considerable 31% in the last month, reversing a fair amount of their...
Narratiefupdate • Jan 24
OWLT: Liquidity And New Coverage Models Will Support Future Execution
Narrative Update: Owlet Analyst Price Target Shift Analysts have lifted their price target on Owlet from US$16 to US$17, reflecting updated models that factor in recent target increases on the Street and comfort with assumptions around fair value, discount rate, and a higher future P/E multiple. Analyst Commentary Recent Street research has tilted constructive on Owlet, with bullish analysts lifting price targets and updating their models following new company information and a transfer of coverage.Narratiefupdate • Jan 09
OWLT: Liquidity And Regulatory Progress Will Support Execution While Risks Remain
Analysts have lifted their price target on Owlet to US$16.00 from US$14.88, citing refreshed models that factor in recent price target increases from firms updating coverage and highlighting added liquidity to support R&D into 2026. Analyst Commentary Recent Street research has trended constructive on Owlet, with higher price targets reflecting refreshed coverage models and a focus on liquidity and execution into 2026.Narratiefupdate • Dec 15
OWLT: FDA Focus And Global Expansion Will Shape Balanced Risk Profile
Analysts have raised their fair value estimate for Owlet from $11.00 to $14.00 per share, citing stronger projected revenue growth, improved liquidity from a recent stock offering, and an FDA highlighted competitive moat that supports a higher long term price target. Analyst Commentary Recent research commentary has underscored a more constructive outlook on Owlet, with price targets moving higher following what was described as a solid quarter and improved balance sheet flexibility.Analyseartikel • Dec 05
There's Reason For Concern Over Owlet, Inc.'s (NYSE:OWLT) Massive 67% Price Jump
Owlet, Inc. ( NYSE:OWLT ) shares have continued their recent momentum with a 67% gain in the last month alone. The...Narratiefupdate • Dec 01
OWLT: Regulatory Momentum And FDA Approval Will Drive Market Leadership Forward
Analysts have increased their price target for Owlet to $15.50 from $12.00, citing a solid quarter, improved liquidity, and the company's status as the only FDA-approved over-the-counter infant monitoring device as key drivers for their more favorable outlook. Analyst Commentary Recent analyst perspectives on Owlet reflect a mixed but largely positive sentiment following the company's most recent financial results and regulatory developments.Narratiefupdate • Nov 17
OWLT: Regulatory Approvals And Increased Liquidity Will Support Long-Term Market Leadership
Analysts have raised their price target for Owlet from $13.20 to $14.83. They cite stronger revenue growth, improved profitability, and increased liquidity following the company's solid recent quarter.Analyseartikel • Oct 07
Further Upside For Owlet, Inc. (NYSE:OWLT) Shares Could Introduce Price Risks After 31% Bounce
Owlet, Inc. ( NYSE:OWLT ) shares have had a really impressive month, gaining 31% after a shaky period beforehand. The...Narratiefupdate • Aug 09
Telehealth Partnerships And AI Insights Will Broaden Digital Health Markets
Driven by strong consumer demand for its FDA-cleared Dream Sock and a unique competitive position, analysts have raised Owlet’s price target from $12.30 to $13.20. Analyst Commentary The $300 Dream Sock is currently a best-selling smart baby monitor on Amazon, demonstrating strong consumer traction.Analyseartikel • Jun 14
Investors Still Aren't Entirely Convinced By Owlet, Inc.'s (NYSE:OWLT) Revenues Despite 34% Price Jump
Owlet, Inc. ( NYSE:OWLT ) shares have continued their recent momentum with a 34% gain in the last month alone. The last...
Nieuw narratief • Apr 10
Dream Sock, BabySat, And Company360 Will Expand Global Healthcare Access
Owlet's FDA and CE approvals pave the way for global market expansion, boosting international revenue potential.Analyseartikel • Oct 18
Many Still Looking Away From Owlet, Inc. (NYSE:OWLT)
Owlet, Inc.'s ( NYSE:OWLT ) price-to-sales (or "P/S") ratio of 1x might make it look like a strong buy right now...Analyseartikel • Jul 18
Investors Continue Waiting On Sidelines For Owlet, Inc. (NYSE:OWLT)
With a price-to-sales (or "P/S") ratio of 0.7x Owlet, Inc. ( NYSE:OWLT ) may be sending very bullish signals at the...Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 186 | 4 | N/A | N/A | 1 |
| 12/31/2027 | 145 | -1 | N/A | 2 | 5 |
| 12/31/2026 | 120 | -6 | N/A | -4 | 5 |
| 3/31/2026 | 107 | -48 | -11 | -10 | N/A |
| 12/31/2025 | 106 | -42 | -12 | -11 | N/A |
| 9/30/2025 | 100 | -42 | -8 | -7 | N/A |
| 6/30/2025 | 90 | -52 | -14 | -13 | N/A |
| 3/31/2025 | 84 | -17 | -15 | -14 | N/A |
| 12/31/2024 | 78 | -17 | -12 | -11 | N/A |
| 9/30/2024 | 79 | -11 | -16 | -16 | N/A |
| 6/30/2024 | 66 | -11 | -14 | -13 | N/A |
| 3/31/2024 | 58 | -19 | -18 | -18 | N/A |
| 12/31/2023 | 54 | -33 | -24 | -24 | N/A |
| 9/30/2023 | 45 | -49 | -32 | -32 | N/A |
| 6/30/2023 | 53 | -61 | -43 | -42 | N/A |
| 3/31/2023 | 58 | -63 | -64 | -63 | N/A |
| 12/31/2022 | 69 | -79 | -83 | -81 | N/A |
| 9/30/2022 | 55 | -84 | -79 | -77 | N/A |
| 6/30/2022 | 69 | -99 | -83 | -81 | N/A |
| 3/31/2022 | 75 | -93 | -64 | -61 | N/A |
| 12/31/2021 | 76 | -72 | -43 | -41 | N/A |
| 9/30/2021 | 99 | -53 | -41 | -40 | N/A |
| 6/30/2021 | 89 | -20 | -19 | -18 | N/A |
| 3/31/2021 | 82 | -16 | -8 | -7 | N/A |
| 12/31/2020 | 75 | -11 | -1 | 0 | N/A |
| 12/31/2019 | 50 | -18 | N/A | -16 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat OWLT de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat OWLT de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat OWLT de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van OWLT ( 18% per jaar) zal naar verwachting sneller groeien dan de markt US ( 11.7% per jaar).
Hoge groei-inkomsten: De omzet van OWLT ( 18% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van OWLT naar verwachting over 3 jaar hoog zal zijn
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/21 14:50 |
| Aandelenkoers aan het einde van de dag | 2026/05/21 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Owlet, Inc. wordt gevolgd door 8 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Allen Lutz | BofA Global Research |
| James Suva | Citigroup Inc |
| Ilya Zubkov | Freedom Broker |